1. GSK reported Q4 sales of $10.40 billion, beating analyst expectations. 2. Vaccine sales fell 14%, with Arexvy significantly impacted by low demand. 3. Specialty Medicines grew 14%, primarily driven by HIV and asthma drug sales. 4. GSK plans £2 billion share buyback over 18 months, boosting EPS outlook. 5. Long-term sales outlook raised to over £40 billion by 2031.
FAQ
Why Bullish?
GSK's better-than-expected sales and share buyback illustrate solid financial health, similar to past recovery trends.
How important is it?
The financial results and future growth potential could lead to increased investor confidence in GSK.
Why Long Term?
The guidance for growth and significant share buybacks may take time to stabilize stock prices.